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Abstract
Background: Recently, trials addressing noisy measurements with diagnosis occurring by exceeding thresholds
(such as diabetes and hypertension) have been published which attempt to measure carryover - the impact that
treatment has on an outcome after cessation. The design of these trials has been criticised and simulations have been
conducted which suggest that the parallel-designs used are not adequate to test this hypothesis; two solutions are
that either a differing parallel-design or a cross-over design could allow for diagnosis of carryover.
Methods: We undertook a systematic simulation study to determine the ability of a cross-over or a parallel-group
trial design to detect carryover effects on incident hypertension in a population with prehypertension. We simulated
blood pressure and focused on varying criteria to diagnose systolic hypertension.
Results: Using the difference in cumulative incidence hypertension to analyse parallel-group or cross-over trials
resulted in none of the designs having acceptable Type I error rate. Under the null hypothesis of no carryover the
difference is well above the nominal 5 % error rate.
Conclusions: When a treatment is effective during the intervention period, reliable testing for a carryover effect is
difficult. Neither parallel-group nor cross-over designs using the difference in cumulative incidence appear to be a
feasible approach. Future trials should ensure their design and analysis is validated by simulation.
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Background
Hypertension and diabetes are responsible for signifi-
cant mortality, morbidity, and cost in both developed and
developing countries [1]. Rather than intervening after
these high-risk conditions develop, it would be preferable
to intervene to prevent incident hypertension and dia-
betes. In this paper we discuss trial design for evaluating
interventions that prevent hypertension or diabetes.
Reliably estimating carryover effects requires that inci-
dent hypertension is diagnosed without differential bias
by treatment group, and rapidly enough to distinguish
zero, short, and long-term carryover. Stephen Senn
defines “direct effects” as the effect of a treatment while
administered and “residual effects” as forms of carryover
which occur after treatment has ceased [2]. We define
carryover as these “residual effects.” This paper is a sys-
tematic simulation study where we attempt to find more
*Correspondence: sstu011@aucklanduni.ac.nz
The Department of Statistics, The University of Auckland, Private Bag 92019,
Auckland, 1142 New Zealand
robust methods with which to test a carryover hypothesis
by focussing on altering various parameters and analysing
Type I error rates. For concreteness, we describe the study
designs in terms of systolic blood pressure (BP) and hyper-
tension, but the results transfer to other incident events
defined by thresholds in similar ways.
This paper is a systematic simulation study where we
attempt to find more robust methods with which to test
a carryover hypothesis by focussing on altering various
parameters and analysing Type I error rates. For concrete-
ness, we describe the study designs in terms of systolic BP
and hypertension, but the results transfer to other incident
events defined by thresholds in similar ways.
The question of carryover effects is obviously of inter-
est for intensive, short-duration lifestyle interventions, but
the statistical issues were in fact first studied in the context
of a pharmacologic intervention. The Trial of Preventing
Hypertension (TROPHY) [3] was conducted to determine
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if two years of treatment with candesartan in prehyperten-
sives reduced the incidence of hypertension over the two
years after treatment ceased.
The TROPHY [3] investigators designed a 4 year trial
in which 809 subjects with systolic BP measurements
between 130 – 139 mm Hg or diastolic BP 85 – 89 mm
Hg were randomised to either treatment or placebo for
2 years. BP measurements were taken every 3 months,
and diagnosis of hypertension occured when any 3 sys-
tolic or diastolic measurements were above the thresh-
old of 140/90 mm Hg. Cumulative incidence in the
placebo arm was 63.0 %, and in the treatment arm
53.2 %. The investigators concluded that “the effect of
active treatment on delaying the onset of hypertension
can extend up to 2 years after the discontinuation of
treatment”.
Issues in the TROPHY design
Due to random variation, the control arm of the trial
is more likely to have measurements above the thresh-
old than the treatment group for the initial 2 years. As
TROPHY diagnosed hypertension when 3 measurements
were above the threshold, which is an unusual defini-
tion of hypertension, it resulted in a systemic bias in the
design. This bias prior to the onset of the carryover period
resulted in more diagnoses in the control arm of the study.
The control arm is partially diagnosed after treatment
ends. Participants removed from the control arm during
treatment makes the subsequent two years not compara-
ble. Simulations suggest that TROPHY had an 80 % Type
I error rate [4]. Meltzer (2006) also criticised TROPHY’s
design as having an “idiosyncratic primary endpoint [that]
seriously impairs external applicability.” Persell and Baker
(2006) noted that cumulative diagnosis rates would differ
even with identical underlying BP.
Possible solutions
The Prostate Cancer Prevention Trial is a parallel-group
trial that had to account for many sources of bias [5]. In
this trial 18,882 men were randomised to treatment with
finasteride or placebo. Unfortunately, finasteride impacts
upon PSA levels that are used to diagnose prostate can-
cer. With this complication, it was likely that there would
be differences in the rates of biopsies in the treatment
and control arms of the study. To address this issue, the
investigators used two techniques. First, they required all
participants undergo biopsies at the end of the 7 year
study. With this adjustment, the only remaining concern
was having similar numbers of biopsies for the duration
of the study, prior to the end. The solution the investiga-
tors proposed was to have differing thresholds used for
PSA levels between the treatment and control arms of the
study. High PSA levels were sent to the statistical centre to
determine if a biopsy was necessary [5].
The TROPHY trial investigators could have used a
similar technique to address differing levels of diagnosis
rates. Although impractical, ambulatory BP (were par-
ticipants wear a cuff which measures their BP every
15 - 30 minutes over an extended period of time)
could be used to accurately determine rates of hyper-
tension at the end of the study [6]. Throughout the
study, TROPHY investigators could have utilised differ-
ing thresholds for the treatment and control arms of the
study determined by a statistical centre to ensure sim-
ilar diagnosis rates. Unfortunately, the investigators did
not recognise the inherent bias, so never considered this
solution.
A crossover trial is another possible solution that we
considered. It is plausible that this design allows for
detecting the existence of carryover, and estimating its
cumulative magnitude. The treatment and control arms of
the study experience equal times with lowered BP when
there is no carryover and the numbers of people diag-
nosed in both arms would be approximately equal at
the same time from the start of treatment. Any carry-
over effect would result in lower cumulative incidence
in the treatment-first arm, by an amount that depends
on the magnitude and duration of the carryover effect.
Although it is unusual to use a cross-over design for
studying an irreversible outcome, other recent examples
exist [7, 8].
Simple comparisons of diagnosis rates in crossover tri-
als are frequently used to determine treatment effects
[9]. We explore this methodology to see if it correctly
identifies carryover. We test an analysis for determining
carryover when the effect of treatment is known. This
differs from the norm, which determines the effect of
treatment in the presence of carryover. We want to deter-
mine if detection of carryover is possible solely using
design.
Carryover has been an important topic in the literature
on cross-over trials, but primarily as a nuisance factor.
That is, trials have been designed so that the carryover
effect need not be known when estimating the effect of an
intervention during the treatment period.
Even with this goal, it is controversial whether existing
cross-over designs can usefully handle carryover effects.
Stephen Senn cautions that “including carry-over in the
model has a disastrous effect on efficiency” [8]. Two-
period cross-over designs have been criticised as having
low power [10–13]. Tests for carryover involving more
complex designs are faulted for unrealistic assumptions
[10, 11] — namely, that carryover occurs for at most one
period, or that carryover has equal effect throughout all
subsequent periods. Stephen Senn laments “that little has
appeared ... on the subject of modelling for carry-over [sic]
that is more grounded in clinical and pharmocological
reality” [2].
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Difficulties in measuring carryover
BP varies throughout the day, over the year, and with a
range of outside influences and non-negligible measure-
ment error [14–19]. Diagnosing hypertension based on a
single measurement will introduce unacceptable levels of
noise, but averaging multiple measurements taken over
a long interval makes it impossible to localise incident
hypertension accurately in time. A practical study design
must compromise and define hypertension in terms of a
small number of measurements taken at relatively infre-
quent intervals. A further complication is that, for ethical
reasons, an individual who crosses the diagnostic thresh-
old for hypertension must receive open-label treatment
that will change all future BP measurements and make
their future data effectively useless in diagnosing hyper-
tension.
In this paper we consider a univariate measurement,
systolic BP, rather than the bivariate measurement (sys-
tolic, diastolic) used in TROPHY and in the prior simula-
tion studies.
In section ‘Methods’ we explain how we generated data,
designed studies, and diagnosed hypertension. Section
‘Results and discussion’ discusses pertinent results and
section ‘Crossover’ discusses where crossover designs
encounter problems. Section ‘Conclusions’ summarises
our results and suggests further research.
Methods
Generating data
Wemodel systolic BP (Yit for individual i at time t) as nor-
mally distributed around an individual-specific long-term
average trend
Yit = ai + bit + ciXit + diZit + it (1)
where Yit is the BP measurement, ai ∼ Unif (125, 140),
bi ∼ N(0,), ci estimates the treatment effects, di esti-
mates the carryover, Xit is 1 if person i is on treatment
at time t and 0 otherwise, and Zit starts at 1 when some-
one stops treatment and decreases linearly to 0 over the
carryover period. The reason for the uniform distribution
on the individual random intercepts is that entry into the
study is based on BP thresholds.
Figure 1 shows some possible models for lengths of car-
ryover in a four year study of hypertension. As we can
see from the graph, BP is lowered during treatment with
medication. At the end of treatment BP returns either
quickly to a normal trend, or more gradually, depend-
ing upon if carryover does exist and the length. Reliably
estimating carryover effects requires that incident hyper-
tension is diagnosed without differential bias by treatment
group, and rapidly enough to distinguish zero, short, and
long-term carryover. In terms of our model the Zit are
altered.
Fig. 1 Systolic BP simulation with and without carryover. There are 5
different lengths of carryover — 0, 0.5, 1, 1.5, and 2 years. A carryover
of 0 (blue green) is a scenario with no carryover effect
Study design
Parallel-group designs have not adequately accounted for
the complexities of testing a carryover hypothesis; we try
to determine if they can. We completed two sets of sim-
ulations — one involving altering inclusion criteria, the
other, altering other parameters — then analysis of false
positives and power were done in each to determine the
effectiveness of the design.
In a two-period two-treatment crossover trial half the
subjects receive treatment A first then crossover to treat-
ment B [20] as demonstrated by Fig. 2. For our purposes,
treatment A lowers BP while treatment B involves placebo
only. Here we see 3 possibilities: treatment second, treat-
ment first and 1.5 years carryover, and treatment first and
no carryover.
We conducted both parallel-group and crossover simu-
lations to evaluate the tests for the presence of carryover
effect and the estimates of its magnitude. Both sets of
simulations began with a random number distributed uni-
formly between 125 – 140 mm Hg as the participants in
the TROPHY trial were prehypertensive [3]. From here a
trend is used as BP increases over time, [21, 22] we used
a trend of 0 , 1, and 2 mm Hg per year which is similar to
what has been used in simulations which have replicated
TROPHY [4, 23]. BP is variable due to both measurement
error and intra-individual variability which we combined
to assume normally distributed standard deviations of
3, 5, and 7 mm Hg [4, 23]. We used treatment effects
of −5 and −10 mm Hg. Measurements were taken either
3 monthly, 6 monthly, or yearly and carryovers of length
0, 0.5, 1, 1.5, and 2 years were assumed. Treatment length
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Fig. 2 Above, two groups receive treatment first with no carryover
and a carryover of 1.5 years, the other group treatment second.
Similar diagnosis rates between the treatment first without carryover
and treatment second would allow for detection of carryover
was 2 years for the cross-over trial which is the length of
time participants received treatment in TROPHY [3]. For
the parrallel-group trial, the duration of the treatment was
either 1, 1.5, 2, 2.5, or 3 years [4].
Simulations for the parallel-group design also looked at
varying the inclusion criteria, by sampling from a uniform
distribution with the baseline BP from 110–140, 120–140,
or 130–140 mm Hg. We fixed the design at 2 years of
treatments [3], 1 mm Hg per year trend in BP [4], and a
standard deviation of 5 mm Hg [4]. The carryover dura-
tion was 0, .5, 1, 1.5, or 2 years [3], measurements 3
monthly, 6 monthly, or yearly [4].
The simulations produced an estimate of the cumulative
incidence of diagnosis in the two trial arms. The Type I
error rate (and the power, not reported) were computed
from these two cumulative incidences and the sample size
using standard formulas for power calculation [24].
A three arm trial with combination parallel and
crossover was also simulated where one arm received
treatment first, another treatment second, and the third
no treatment. The same values and parameters were used
for this simulation as those above.
Rules
In addition to the formula for BP it was necessary to
develop criteria to establish when a person became hyper-
tensive. We analysed five feasible criteria for diagnos-
ing hypertension using a threshold of 140 mm Hg: if
one measurement was above, if two consecutive mea-
surements were above, if the average of two consecutive
measurements were above, if any three measurements
were above, and if the average of three consecutive mea-
surements were above. To illustrate the importance of
measurement error we also considered a rule that diag-
nosed hypertension when both the measured systolic
pressure and the underlying long-term BP were above
threshold. This rule is not of practical use, although it
could be implemented by averaging a large number of
measurements over a period of days for anyone who had a
single measurement over 140 mm Hg.
Results and discussion
Parallel-group design
Figure 3 shows the rates of false positives across four rules
studied, which are significantly higher than the accepted
rate of 5 %. The x axis of each graph tells us the length of
time participants received treatment, with differing mea-
surement standard deviations found in rows and columns
signifying varying rules. The line types distinguish the
frequency of measurements, as indicated in the key. All
the results have trend of 1 mm Hg per year. Figure 3
shows some general trends: as the error increases the rate
of false positives also increases, less frequent measure-
ments result in increased rates of false positives, and as the
duration of treatment increases so does the rate of false
positives. The last suggests that these designs are unable
to distinguish between the treatment period and carry-
over period. In general, type I error rate is inflated except
for the smallest measurement error and shortest period of
active treatment. Generalising to a bivariate measurement
will make the design perform worse.
Two rules are omitted from the graph. One, where peo-
ple are diagnosed when 3 measurements are above the
threshold, has been studied previously [23, 25, 26], the
other is the infeasible rule that uses the true long-term-
average BP. This rule is the only one that does achieve
close to nominal Type I error rate. Additional files 1 and 2
are the R code used in our simulation process.
Parallel-design— inclusion criteria
Measurement error can lead to false positive diagnosis
only when true BP is relatively close to the threshold, so
varying inclusion criteria for baseline long-term-average
BP were considered. Figure 4 shows difference in cumula-
tive incidence of diagnosis for three inclusion thresholds
(110, 120, 130 mmHg) in the presence and absence of car-
ryover. Each line colour shows differing treatment effects,
as indicated by the key. The 3 columns indicate differ-
ing measurement schedules per the labels above, and the
x axis indicates the length of carryover. Figure 4 demon-
strates several results: treatment effects of −10 mm Hg
results in fewer people being diagnosed in the treatment
arm, lowering the lower bound of the inclusion criteria for
baseline systolic BP results in fewer people diagnosed, and
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Fig. 3 This graph shows estimated rates of false positives in a parallel-group design for the rules mentioned, most are far from the normal 5 %
more frequent measurements allows limited distinction
between short and longer carryovers. Including partic-
ipants with lower BP reduces the estimated carryover
effect under the null hypothesis, but also under the alter-
native hypothesis. Additional file 3 is the R code used to
simulate these trials.
Crossover design
Figure 5 shows the Type I error rate for five rules sudied,
all of which are higher than the nominal 5 % rate. The x
axis of each graph denotes the trend in BP, differing line
types indicate measurement schedules, per the key. Each
rule recieves its own column, while standard deviations
are in rows. As none of the rules even has suitable Type I
error rate, we do not present results on the power of the
tests or the estimates of carryover magnitude. The rule
which involves removing variation is not included; even
this design had high Type I error. Additional files 4 and 5
are the R code used to simulate crossover trials.
Figure 5 has a few notable trends. In most graphs, the
trials represented by points with trend 0 mm Hg per year
(those to the left above 0 on the x axis) have false positive
rates close to the boundary of 5 %. Inmost graphs, of those
with trend 0 mm Hg per year, the lighter points are closer
to 5 % which shows that more frequent measurements
are more likely to have appropriate rates of false positives.
Trials on the top row (simulated with an error of 7 mm
Hg) results in diagnosis rates with little consistency.
Combination of parallel and crossover
As the parallel group design has positive bias [4, 23] and
the crossover design has negative bias (which will be dis-
cussed in section ‘Crossover’), there is the potential for
combining the two and having the bias cancel out. The
combination design would be a two period, three arm
crossover trial in which 1 arm receives treatment for
the first period and placebo the second, another receives
placebo for both periods, and the last placebo followed by
treatment.
Our simulations showed that this combination cannot
be made to work reliably. The rules tested demonstrated
inconsistent differences in relation to increasing amounts
of carryover (data not shown). Additional files 6 and 7 are
the R code used to simulate combination trials.
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Fig. 4 Impact of altering inclusion criteria upon differences in cumulative diagnosis rates in a parallel-group design. The x axis indicates the length of
carryover
Crossover
Figure 6 illustrates why the crossover design fails and why
even slight trends over time are problematic. The graph
shows noise-free BP patterns for two treatment:control
pairs of individuals, one with baseline systolic pressure of
approximately 137.5 mm Hg and one with baseline sys-
tolic pressure of approximately 139 mm Hg, and with a
trend of 1 mm Hg/year. The trend destroys the symme-
try of the design: in the pair with higher baseline pressure,
the control individual is diagnosed during the first period
and is not available in the second period. In the pair with
lower baseline pressure both individuals are available for
both time periods. The effect of the trend is to selectively
remove higher-risk individuals from the control-first arm
of the trial.
Figure 6 shows that the difference in cumulative diagno-
sis without carryover in this example is biased. The dotted
lines indicate that the participants have started treatment
as systolic hypertension was diagnosed at the last mea-
surement. Of the control pairs only the one with high
base line pressure is diagnosed in the first period and not
available in the second, in the treatment pairs both are
diagnosed in the second period. The effect of the trend
is to selectively remove higher-risk individuals from the
control-first arm of the trial and results in a bias when
testing for carryover.
Figure 5 is consistent with the above. When there is no
trend in the data, less error, and measurements are fre-
quent, rates of false positives are close to acceptable which
we saw in our simulations in section ‘Crossover design’.
Systolic BP with a trend of 0 mm Hg is possible in a
short study but not likely over a long period which limits
applicability.
Conclusions
In conclusion, a simple comparison of cumulative inci-
dence in a cross-over provides a valid test for carryover
effects only when there is no trend in the underlying out-
come variable (or the trial is too short for the trend to
be apparent). Unfortunately, BP in prehypertensives and
fasting glucose in prediabetics both exhibit non-negligible
trends.
Our results have been framed in terms of a discrete
intervention period where the treatment effect is constant
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Fig. 5 Above are the Type I error rates for differing rules and standard deviations in a crossover design. The x axis denotes trend and differing line
types indicate measurement schedules
Fig. 6 Control high and treatment high have similar starting values as
does control low and treatment low. Both treatments are diagnosed
as hypertensive while only the control high is diagnosed. This impacts
upon our ability to determine if there is a carryover as the treatment
group is more likely to be diagnosed irrelevant of the carryover
over time, as might be plausible for a pharmacological
intervention. Introducing the additional complications of
time-varying effect that would be expected in lifestyle
interventions would complicate the analysis but would be
unlikely to remove the bias.
These results will depend on the variability in systolic
and diastolic BP over time, and on the way in which
any carryover effect decreases with time. We have used a
simplified model for this which may limit our results.
It does not appear possible to design a parallel-group
or cross-over study where carryover effects of this sort
can be estimated by simple comparisons of cumulative
incidence. Valid tests for carryover effects will require
the development of new analytic techniques; the fact
that post-diagnosis observations are removed based only
on the values of pre-diagnosis observations means that
they are Missing At Random and suggests a mixed-model
approach.
Additional files
Additional file 1: Was used to simulate parallel trials. (R 5 kb)
Additional file 2: Was used to simulate parallel trials where diagnosis is
defined using the BP measurements without error. (R 5 kb)
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Additional file 3: Was used to simulate parallel trials where the lower
bound of the inclusion criteria varied. (R 4 kb)
Additional file 4: Was used to simulate crossover trials. (R 5 kb)
Additional file 5: Was used to simulate crossover trials where diagnosis is
defined using the BP measurements without error. (R 5 kb)
Additional file 6: Was used to simulate trials which included both
crossover, parallel, and control arms. (R 3 kb)
Additional file 7: Was used to simulate trials which included both
crossover, parallel, and control arms when diagnosis is determined by
using the BP measurements without error. (R 5 kb)
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